June 11, 2020

12:00pm ET


Utilize our networking app to schedule one-to-one online meetings. Learn more.

1:00pm ET

Partnerships: Identifying Effective Models

Developing cell and gene therapies is extremely complex – there is no roadmap. Partnering is a critical decision for biotechs in this space and identifying the right one for your business means increasing program efficiencies, implementing acceleration options, and saving costs. This session will discuss different partnering models, incorporating integrated guidance, and questions a biotech should be asking: what to expect, how to avoid the pitfalls and overcome challenges, and what you should look for in a partner.


Bruce Levine – Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania & Co-founder, Tmunity

David Horton – Director, Strategic and Scientific Affairs, Medpace

Delfi Krishna – Director, Cell and Gene Therapy Platform: R&D Strategy, Portfolio and Operations, GSK

John Younger – VP, Science and Technology, University City Science Center

2:00pm ET

Technology Evaluation: When & How to Innovate

Advanced gene-editing and analytical technologies have had exciting progress in the cell and gene therapy space. How can you address the challenges in implementation and production of gene therapy products? This session will delve into approaches to advance your therapy safely.


Audrey Greenberg – Co-founder & Executive Managing Director, The Discovery Labs

Jeffrey Castelli – Chief Portfolio Officer and Head of Gene Therapy, Amicus Therapeutics

Gustavo Mahler – Managing Partner, Dynamk Capital

Tom Wilton – Chief Business Officer, Carisma Therapeutics

3:00pm ET

Regulatory Pathways

With the increase of cell and gene therapy work, being at the forefront presents opportunities and challenges. In this session, panelists will dissect some of the intricacies of understanding regulatory expectations and how to approach the dilemma of technology outpacing regulations. We’ll cover working with regulators, using in-house and external regulatory guidance, and what the future of the industry holds as therapies receive approvals.


Diane Blumenthal – Head of Technical Operations, Spark Therapeutics

Snehal Naik – Associate Director, Global Regulatory Affairs: Regenerative Medicines and Advanced Therapies, CAR-T and Microbiome, Janssen Research and Development

Sally Wang Liang – VP of Business Development, Zonsen PepLib Biotech

4:00pm ET


Utilize our networking app to schedule one-to-one online meetings. Learn more.